市場調査レポート

次世代シークエンシング市場

Next Generation Sequencing Markets (Systems, Consumables, Services, Competitive Analysis, Trends, Platforms)

発行 Kalorama Information 商品コード 324189
出版日 ページ情報 英文 533 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
次世代シークエンシング市場 Next Generation Sequencing Markets (Systems, Consumables, Services, Competitive Analysis, Trends, Platforms)
出版日: 2016年09月07日 ページ情報: 英文 533 Pages
概要

当レポートでは、世界の次世代シークエンシング市場について調査し、システム・消耗品・サービス市場の規模と予測、地域別の分析、地域分布、主要企業の市場シェア、プラットフォームごとのブランド所有、およりDNAシークエンシング市場などについてまとめ、お届けいたします。

第1章 エグゼクティブサマリー

第2章 イントロダクション

第3章 シークエンシング技術

  • サンガ―シークエンシング
  • 次世代シークエンシング
  • MPSS(Massively Parallel Signature Sequencing)
  • パイロシークエンシング
  • 454 シークエンシング技術
  • SBS(Sequencing by Synthesis)法
  • SOLiD(Supported Oligonucleotide Ligation and Detection)
  • イオントレントシークエンシング
  • tSMS(True Single Molecule Sequencing )
  • SMRT(Single Molecule Real Time)シークエンシング
  • DNAナノボールシークエンシング
  • ナノポアシークエンシング
  • その他のシークエンシング技術
  • サンプル調製
  • 情報技術
  • ワークフローもしくはプラットフォームの回答サンプル

第4章 シークエンシング用途

  • 研究、ドラッグディスカバリーおよび開発
  • シークエンシングの診断用途
  • 直販ジェネリック検査産業

第5章 契約:シークエンシング企業

  • シークエンシング企業の投資・財務契約
  • その他企業との契約
  • シークエンスング企業の買収
  • その他の主な合意

第6章 シークエンシングの診断への応用:市場促進因子・課題

  • 技術ハードルの克服:サンプル調製・データ分析
  • 次世代シークエンシング市場の促進因子
  • 研究市場に販売する企業が直面する課題と障壁
  • 診断市場に販売する企業が直面する課題と障壁
  • 将来の展望

第7章 DNAシークエンシング市場分析

  • DNAシークエンシングの市場概要
  • シークエンシング市場:地域分布
  • ブランドの所有
  • DNAシークエンシング市場:研究vs.臨床用途

第8章 企業プロファイル:次世代シークエンシング企業

図表リスト

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: KLI15104387

DNA sequencing has attracted many companies, researchers, and investors. The sequencing market, comprised of the next generation sequencing market and capillary electrophoresis sequencing systems (based on the early Sanger sequencing method), is a large and rapidly growing market. Clinical applications of DNA sequencing are being developed and commercialized. Evidence of the promise and current excitement with DNA sequencing can be seen with many recent events. Next Generation Sequencing Markets examines the segments of the sequencing market, including sequencing instruments plus consumables and also service revenue such as from extended instrument service contracts, with analysis of the full sequencing market including:

  • Worldwide Sequencing Market Product Revenues (Instruments and Consumables), 2015 and 2020
  • Sequencing Market, Worldwide, 2015 and 2020 (Instrument Revenue, Consumables Revenue, Services Revenue, Total Market)
  • Market Share of Sequencing Market, By Company (Instruments, Consumables, Services Relating to Supporting Products)
  • Sequencing Market by Geographical Region, Worldwide, 2015 and 2020 (North America, Europe, Asia, Rest of World, Total Market)
  • Next Generation Sequencing System Ownership by Country, Percentage (United States, China, Germany, UK, South Korea, Spain, Canada, France, Australia, Netherlands, Italy, Taiwan, Brazil, Japan, India, Sweden, Belgium, Denmark, Switzerland, Singapore, Saudi Arabia, Others)
  • Next Generation Sequencing System Ownership by Brand (HiSeq2000, Genome Analyser, Roche 454, ABI SOLiD, Ion Torrent, MiSeq, Ion Proton, Pacific Biosciences, Oxford Nanopore MinION, Polonator, NextSeq)
  • Percent of End Users (Academic & Government versus Commercial, Non-Profit & Hospital), 2014, 2015, and 2018 (projected)
  • Research Sequencing Market - Types of Sequencing: Targeted or Whole Exome Sequencing versus de novo or Whole Genome Sequencing (2015)
  • Clinical Sequencing Market by Disease Category, 2015, Percentage (Genetic Testing/Inherited Disorders, Other Disorders)
  • Clinical Sequencing Market by Disease Category, 2020, Percentage (Oncology, Genetic Testing/Inherited Disorders, Infectious Disease, Other Disorders)
  • Investments in Next Generation Sequencing Companies, 2015 and First Half of 2016

Growth in the research market and also in clinical applications of next generation sequencing - as demonstrated by the rapid growth of the market leader and the market as a whole - is being driven by several factors. As discussed in the report, these include the following market drivers:

  • Advances in Technology
  • Increasing Number of Clinical Applications for Next Generation Sequencing
  • Cancer Diagnostic Market Drivers
  • Genetic Analysis [Inherited Disorders, Prenatal and Postnatal Diagnostics] Market Drivers
  • Infectious Disease Diagnostic Market Drivers

DNA sequencing has successfully penetrated the research market. This market is expected to continue to grow, despite funding issues and other challenges. DNA sequencing is also penetrating the clinical diagnostic market. The sequencing field has entered an exciting time where it is now becoming possible to realize some of the potential benefits long dreamed about by researchers and companies in this field, though improvements in sequencing technology are still needed in order to make sequencing based diagnostic tests widely available and used by all physicians.

DNA sequencing has become a competitive field with companies developing or offering newer, proprietary nucleic acid sequencing technologies. The report discusses new technologies, among these Massively Parallel Signature Sequencing (MPSS), Pyrosequencing, 454 Technology, Sequencing by Synthesis (SBS), Supported Oligonucleotide Ligation and Detection (SOLiD), Ion Torrent Sequencing, Single Molecule Real Time (SMRT) Sequencing, DNA Nano Ball Sequencing, and Nanopore Sequencing. New technologies are summarized as well, including:

  • Current and Emerging Sequencing Technologies and Platforms
  • Selected Companies Developing/Marketing Products for NGS Sample or Library Preparation
  • Selected Companies Developing/Marketing NGS Information Technology Solutions
  • Selected Companies Developing NGS Sample-to-Answer (Sample-to-Insight) Platforms
  • Selected Companies Developing Rapid NGS Assays or Platforms

Most currently available clinical tests based on next generation sequencing are laboratory developed tests (LDTs). The first next generation sequencing system and in vitro diagnostic tests have been cleared by the FDA, and more will follow. The next generation sequencing clinical diagnostic market is poised for continued rapid growth over the next several years.

Next generation sequencing is increasingly being used in the field of personalized medicine and companion diagnostics. For example, in oncology, pharmaceutical companies are developing and commercializing a growing number of targeted therapies. This has generated a need for assays that detect the presence or absence of increasingly more genetic markers, all from a small sample of tissue. In other words, multiplexed assays and/or panels are needed. This, in turn, has led to increased interest in technologies such as next-generation sequencing, which can be used to interrogate a large number of genes in a single assay. The report covers NGS applications in cancer diagnostics, including NGS-based tests for oncology and liquid biopsies; genetic analysis - inherited disorders, prenatal and postnatal diagnostics; infectious disease diagnostics; human leukocyte antigen (HLA) testing; and other diagnostic applications of sequencing, including in the direct-to-consumer genetic testing industry. The report notes the following:

  • Selected Companies Offering Products/Services for Applications of Next Generation Sequencing in Oncology
  • Selected Companies Developing and/or Marketing Liquid Biopsy Assays
  • Selected Companies Offering Products/Services for Applications of Next Generation Sequencing in Genetic Analysis [Inherited Disorders, Prenatal and Postnatal Diagnostics]
  • Selected Companies Offering Products/Services for Applications of Next Generation Sequencing in Infectious Diseases
  • Selected Companies Offering Products/Services for Applications of DNA Sequencing in Human Leukocyte Antigen (HLA) Testing
  • Selected Companies Offering Products/Services for Applications of Next Generation Sequencing in Other Diagnostic Applications

Collaborations are an essential part of the growing sequencing market. The impact of deals in the sequencing marketplace is discussed in detail in this report:

  • Selected Investment and Financing Agreements in Next Generation Sequencing Companies [Includes IT Companies in NGS]
  • Selected Acquisitions of Next Generation Sequencing Companies [Includes IT Companies in NGS]
  • Selected Agreements between Next Generation Sequencing Companies and Diagnostic Companies or Clinical Laboratories [Includes IT Companies in NGS]
  • Examples of Diagnostic Companies and Clinical Laboratories That Have Made Agreements in Next Generation Sequencing
  • Selected Agreements between Next Generation Sequencing Companies and Pharmaceutical or Biopharmaceutical Companies [Includes Contract Research Organizations Providing Services to Pharma Companies]
  • Selected Pharmaceutical and Biopharmaceutical Companies Using or Active in Next Generation Sequencing
  • Selected Company Agreements between Two Next Generation Sequencing Companies [Includes IT Companies in NGS]
  • Selected Other Next-Generation Sequencing Company Agreements in Next Generation Sequencing [Includes IT Companies in NGS]
  • Selected Next Generation Sequencing Company Agreements with Academic or Other Non-Profit Organizations [Includes IT Companies in NGS]

Profiles of companies in Next Generation Sequencing Markets (Systems, Consumables, Services, Competitive Analysis, Trends, Platforms) reflect the wide range next generation sequencing products, including sample preparation, sequencing, and data analysis. Companies profiled include:

  • 10x Genomics, Inc.
  • 23andMe, Inc.
  • Abbott Laboratories
  • ACT Genomics Co., Ltd.
  • Adaptive Biotechnologies Corporation
  • Admera Health
  • Advanced Biological Laboratories (ABL), S.A.
  • Agilent Technologies Inc.
  • AltheaDx, Inc.
  • Ambry Genetics Corp.
  • Aperiomics, Inc.
  • Asuragen, Inc.
  • Athena Diagnostics, Inc. (A Quest Diagnostics Business)
  • Base4 Innovation Ltd
  • Beckman Coulter, Inc. (Subsidiary of Danaher Corporation)
  • Becton, Dickinson and Company (BD)
  • BGI
  • Bina Technologies, Inc. (Part of Roche Sequencing)
  • BioDiscovery, Inc.
  • Biomatters Ltd.
  • bioMérieux S.A.
  • bioTheranostics, Inc.
  • Cancer Genetics, Inc.
  • CareDx, Inc.
  • Caris Life Sciences
  • CLC bio (A QIAGEN Company)
  • Color Genomics, Inc.
  • Complete Genomics (A BGI Company)
  • Courtagen Life Sciences, Inc.
  • Cynvenio Biosystems, Inc.
  • DNA Electronics Ltd.
  • Eurofins Genomics
  • Exosome Diagnostics, Inc.
  • Foundation Medicine, Inc.
  • GATC Biotech AG
  • GenapSys, Inc.
  • GenDx
  • GENEWIZ Inc.
  • Genia Technologies, Inc. (Part of Roche Sequencing)
  • Genomic Health, Inc.
  • Genoptix (A Novartis Company)
  • GnuBIO, Inc. (A Bio-Rad Company)
  • GRAIL
  • Guardant Health, Inc.
  • Helix
  • HTG Molecular Diagnostics
  • Human Longevity, Inc.
  • Illumina, Inc.
  • Inivata Ltd.
  • Invitae Corporation
  • Invivoscribe Technologies, Inc.
  • Laboratory Corporation of America (LabCorp)
  • Lasergen, Inc.
  • MolecularMD Corporation
  • Myriad Genetics, Inc.
  • NANTOMICS (Member of the NantWorks ecosystem of companies)
  • Natera, Inc.
  • NeoGenomics, Inc./NeoGenomics Laboratories
  • N-of-One, Inc.
  • OncoDNA S.A.
  • Oncospire Genomics
  • Oxford Nanopore Technologies Ltd.
  • Pacific Biosciences of California, Inc.
  • Pathway Genomics Corporation
  • Personal Genome Diagnostics, Inc.
  • Personalis, Inc.
  • QIAGEN N.V.
  • Quest Diagnostics
  • RainDance Technologies, Inc.
  • Roche
  • Siemens Healthcare Diagnostics
  • Stratos Genomics Inc.
  • Sysmex Corporation
  • Thermo Fisher Scientific, Inc.

Technology advances in knowledge of the genome, and in DNA sequencing technology/platforms, will continue to fuel the growth of diagnostic applications of next generation sequencing in clinical laboratories and companies with CLIA-certified laboratories, and also in IVD companies that sell kits to clinical labs.

Table of Contents

CHAPTER 1: Executive Summary

  • Overview
  • Scope and Methodology
  • Market Overview
  • Future Prospects in the Sequencing Market

CHAPTER 2: Introduction

  • Overview - Next Generation Sequencing Market Is Rapidly Changing
  • History of DNA Sequencing
  • Point-of-View

CHAPTER 3: Sequencing Technology

  • Sanger Sequencing
  • Next-Generation Sequencing
  • Massively Parallel Signature Sequencing (MPSS)
  • Pyrosequencing
  • 454 Technology
  • Sequencing by Synthesis (SBS)
  • Supported Oligonucleotide Ligation and Detection (SOLiD)
  • Ion Torrent Sequencing
  • Single Molecule Real Time (SMRT) Sequencing
  • DNA Nano Ball Sequencing
  • Nanopore Sequencing
  • Other Sequencing Technologies
  • Sequencing Applications/Types of Sequencing
  • Sample or Library Preparation
  • Information Technology
  • Sample-to-Answer (Sample-to-Insight) Workflows or Platforms
  • Rapid Next Generation Sequencing Testing

CHAPTER 4: Sequencing Applications

  • Research, Drug Discovery and Development
  • Clinical Diagnostic Applications of Sequencing
  • Cancer Diagnostics: NGS Based Tests for Oncology
  • Cancer Diagnostics: Liquid Biopsies
  • Genetic Analysis - Inherited Disorders, Prenatal and Postnatal Diagnostics
  • Infectious Disease Diagnostics
  • Human Leukocyte Antigen (HLA) Testing
  • Other Diagnostic Applications of Sequencing
  • Direct-to-Consumer Genetic Testing Industry

CHAPTER 5: Deals - Next Generation Sequencing Companies

  • Investments and Financing Agreements
  • Mergers and Acquisitions
  • Other Corporate Agreements and Collaborations
  • Collaborations/Agreements with Diagnostic Companies and/or Clinical Laboratories
  • Collaborations/Agreements with Pharmaceutical and Biopharmaceutical Companies
  • Collaborations/Agreements between Two Companies in Next Generation Sequencing
  • Other Company Collaborations/Agreements
  • Collaborations and Other Agreements with Universities, Non-Profit Research Institutes and Government

CHAPTER 6: Applying Sequencing to Diagnostics - Market Drivers and Challenges

  • Overcoming Technology Hurdles - Sample Preparation and Data Analysis
  • Advances in Next Generation Sequencing Platforms
  • Next Generation Sequencing Market Drivers
  • Advances in Technology
  • Research Market Drivers
  • Increasing Number of Clinical Applications for Next Generation Sequencing
  • Cancer Diagnostic Market Drivers
  • Genetic Analysis [Inherited Disorders, Prenatal and Postnatal Diagnostics] Market Drivers
  • Infectious Disease Diagnostic Market Drivers
  • Market Drivers for Other Segments of the Diagnostic Market
  • Issues and Hurdles Faced by NGS Companies Selling to the Research Market
  • Issues and Hurdles Faced by Clinical Laboratories Doing NGS
  • Regulation of Next Generation Sequencing-Based In Vitro Diagnostic (IVD) Tests
  • Regulation of Companion Diagnostics
  • Complexities of Companion Diagnostic Tests and Corresponding Therapeutic Products; Harmonization of Companion Diagnostic Tests Across a Class of Targeted Therapies
  • Cost and Reimbursement Issues
  • Competition
  • Future Prospects

CHAPTER 7: Sequencing Market Analysis

  • Sequencing Market Overview
  • Sequencing Market - Geographical Distribution
  • Brand Ownership
  • Sequencing Market - Research versus Clinical Use
  • Sequencing Methods/Applications
  • Clinical Sequencing Market - Disease Indications
  • Analysis of Deals Activity in Next Generation Sequencing

CHAPTER 8: Company Profiles - Next Generation Sequencing Companies

  • 10x Genomics, Inc.
  • 23andMe, Inc.
  • Abbott Laboratories
  • Recent Revenue History
  • Company Overview - With a Focus on Sequencing
  • ACT Genomics Co., Ltd.
  • Adaptive Biotechnologies Corporation
  • Admera Health
  • Advanced Biological Laboratories (ABL), S.A
  • Agilent Technologies Inc.
  • Recent Revenue History
  • Company Overview
  • AltheaDx, Inc.
  • Ambry Genetics Corp.
  • Aperiomics, Inc.
  • Asuragen, Inc.
  • Athena Diagnostics, Inc. (A Quest Diagnostics Business)
  • Base4 Innovation Ltd
  • Beckman Coulter, Inc. (Subsidiary of Danaher Corporation)
  • Revenue History
  • Company Overview
  • Becton, Dickinson and Company (BD)
  • Recent Revenue History
  • Company Overview
  • BGI
  • Bina Technologies, Inc. (Part of Roche Sequencing)
  • BioDiscovery, Inc.
  • Biomatters Ltd.
  • bioMérieux SA
  • Recent Revenue History
  • Company Overview
  • bioTheranostics, Inc.
  • Cancer Genetics, Inc.
  • Recent Revenue History
  • Company Overview
  • CareDx, Inc.
  • Recent Revenue History
  • Company Overview
  • Caris Life Sciences
  • CLC bio (A QIAGEN Company)
  • Color Genomics, Inc.
  • Complete Genomics (A BGI Company)
  • Courtagen Life Sciences, Inc.
  • Cynvenio Biosystems, Inc.
  • DNA Electronics Ltd.
  • Eurofins Genomics
  • Exosome Diagnostics, Inc.
  • Foundation Medicine, Inc.
  • Recent Revenue History
  • Company Overview
  • GATC Biotech AG
  • GenapSys, Inc.
  • GenDx
  • GENEWIZ Inc.
  • Genia Technologies, Inc. (Part of Roche Sequencing)
  • Genomic Health, Inc.
  • Recent Revenue History
  • Company Overview
  • Genoptix (A Novartis Company)
  • GnuBIO, Inc. (A Bio-Rad Company)
  • GRAIL
  • Guardant Health, Inc.
  • Helix
  • HTG Molecular Diagnostics
  • Recent Revenue History
  • Company Overview
  • Human Longevity, Inc.
  • Illumina, Inc.
  • Recent Revenue History
  • Company Overview
  • Inivata Ltd.
  • Invitae Corporation
  • Recent Revenue History
  • Company Overview
  • Invivoscribe Technologies, Inc.
  • Laboratory Corporation of America (LabCorp)
  • Recent Revenue History
  • Company Overview
  • Lasergen, Inc.
  • MolecularMD Corporation
  • Myriad Genetics, Inc.
  • Recent Revenue History
  • Company Overview
  • NANTOMICS (Member of the NantWorks ecosystem of companies)
  • Natera, Inc.
  • NeoGenomics, Inc./NeoGenomics Laboratories
  • Recent Revenue History
  • Company Overview
  • N-of-One, Inc.
  • OncoDNA SA
  • Oncospire Genomics
  • Oxford Nanopore Technologies Ltd.
  • Pacific Biosciences of California, Inc.
  • Recent Revenue History
  • Company Overview
  • Pathway Genomics Corporation
  • Personal Genome Diagnostics, Inc.
  • Personalis, Inc.
  • QIAGEN N.V.
  • Recent Revenue History
  • Company Overview
  • Quest Diagnostics
  • Recent Revenue History
  • Company Overview
  • RainDance Technologies, Inc.
  • Roche
  • Recent Revenue History
  • Company Overview
  • Siemens Healthcare Diagnostics
  • Recent Revenue History
  • Company Overview
  • Stratos Genomics Inc.
  • Sysmex Corporation
  • Recent Revenue History
  • Company Overview
  • Thermo Fisher Scientific, Inc.
  • Recent Revenue History
  • Company Overview

List of Exhibits

1: Executive Summary

  • Table 1-1: Worldwide Sequencing Market Product Revenues (Instruments and Consumables), 2015 and 2020

3: Sequencing Technology

  • Table 3-1: Current and Emerging Sequencing Technologies and Platforms
  • Table 3-2: Selected Companies Developing/Marketing Products for NGS Sample or Library Preparation
  • Table 3-3: Selected Companies Developing/Marketing NGS Information Technology Solutions
  • Table 3-4: Selected Companies Developing NGS Sample-to-Answer(Sample-to-Insight) Platforms
  • Table 3-5: Selected Companies Developing Rapid NGS Assays or Platforms

4: Sequencing Applications

  • Table 4-1: Selected Companies Offering Products/Services for Applications of Next Generation Sequencing in Oncology
  • Table 4-2: Selected Companies Developing and/or Marketing Liquid Biopsy Assays
  • Table 4-3: Selected Companies Offering Products/Services for Applications of Next Generation Sequencing in Genetic Analysis [Inherited Disorders,Prenatal and Postnatal Diagnostics]
  • Table 4-4: Selected Companies Offering Products/Services for Applications of Next Generation Sequencing in Infectious Diseases
  • Table 4-5: Selected Companies Offering Products/Services for Applications of DNA Sequencing in Human Leukocyte Antigen (HLA) Testing
  • Table 4-6: Selected Companies Offering Products/Services for Applications of Next Generation Sequencing in Other Diagnostic Applications

5: Deals - Next Generation Sequencing Companies

  • Table 5-1: Selected Investment and Financing Agreements in Next Generation Sequencing Companies [Includes IT Companies in NGS]
  • Table 5-2: Selected Acquisitions of Next Generation Sequencing Companies[Includes IT Companies in NGS]
  • Table 5-3: Selected Agreements between Next Generation Sequencing Companies and Diagnostic Companies or Clinical Laboratories [Includes IT Companies in NGS]
  • Table 5-4: Examples of Diagnostic Companies and Clinical Laboratories That Have Made Agreements in Next Generation Sequencing
  • Table 5-5: Selected Agreements between Next Generation Sequencing Companies and Pharmaceutical or Biopharmaceutical Companies [Includes Contract Research Organizations Providing Services to Pharma Companies]
  • Table 5-6: Selected Pharmaceutical and Biopharmaceutical Companies Using or Active in Next Generation Sequencing
  • Table 5-7: Selected Company Agreements between Two Next Generation Sequencing Companies [Includes IT Companies in NGS]
  • Table 5-8: Selected Other Next-Generation Sequencing Company Agreements in Next Generation Sequencing [Includes IT Companies in NGS]
  • Table 5-9: Selected Next Generation Sequencing Company Agreements with Academic or Other Non-Profit Organizations [Includes IT Companies in NGS]

7: Sequencing Market Analysis

  • Table 7-1: Sequencing Market, Worldwide, 2015 and 2020 (Instrument Revenue, Consumables Revenue, Services Revenue, Total Market)
  • Table 7-2: Sequencing Market by Geographical Region, Worldwide, 2015 and 2020 (North America, Europe, Asia, Rest of World, Total Market)
  • Figure 7-2: Next Generation Sequencing System Ownership by Country, Percentage (United States, China, Germany, UK, South Korea, Spain, Canada, France, Australia, Netherlands, Italy, Taiwan, Brazil, Japan, India, Sweden, Belgium, Denmark, Switzerland, Singapore, Saudi Arabia, Others)
  • Figure 7-3: Next Generation Sequencing System Ownership by Brand (HiSeq2000, Genome Analyser, Roche 454, ABI SOLiD, Ion Torrent, MiSeq, Ion Proton, Pacific Biosciences, Oxford Nanopore MinION, Polonator, NextSeq)
  • Figure 7-5: Research Sequencing Market - Types of Sequencing: Targeted or Whole Exome Sequencing versus de novo or Whole Genome Sequencing (2015)
  • Figure 7-6: Clinical Sequencing Market by Disease Category, 2015, Percentage (Genetic Testing/Inherited Disorders, Other Disorders)
  • Figure 7-7: Clinical Sequencing Market by Disease Category, 2020, Percentage(Oncology, Genetic Testing/Inherited Disorders, Infectious Disease, Other Disorders)
  • Table 7-3: Investments in Next Generation Sequencing Companies, 2015 and First Half of 2016

8: Company Profiles - Next Generation Sequencing Companies

  • Table 8-1: Abbott Revenues (2013, 2014, 2015)
  • Table 8-2: Agilent Technologies Revenues (2013, 2014, 2015)
  • Table 8-3: Becton, Dickinson and Company (BD) Revenues (2013, 2014, 2015)
  • Table 8-4: bioMérieux Revenues (2013, 2014, 2015)
  • Table 8-5: bioMérieux Revenues (2014 and 2015) - By Region, and by Technology and Application
  • Table 8-6: Cancer Genetics Revenues (2013, 2014, 2015)
  • Table 8-7: CareDx Revenues (2013, 2014, 2015)
  • Table 8-8: Foundation Medicine Revenues (2013, 2014, 2015)
  • Table 8-9: Genomic Health Revenues (2013, 2014, 2015)
  • Table 8-10: HTG Molecular Diagnostics (2014 and 2015)
  • Table 8-11: Illumina (2013, 2014, 2015)
  • Table 8-12: Invitae Corporation Revenues (2013, 2014, 2015)
  • Table 8-13: Laboratory Corporation of America (LabCorp) Revenues (2013,2014, 2015)
  • Table 8-14: Myriad Genetics Revenues (2013, 2014, 2015)
  • Table 8-15: NeoGenomics Revenues (2013, 2014, 2015)
  • Table 8-16: Pacific Biosciences Revenues (2013, 2014, 2015)
  • Table 8-17: QIAGEN Revenues (2013, 2014, 2015)
  • Table 8-18: QIAGEN - Distribution of Sales in 2015
  • Table 8-19: Quest Diagnostics Revenues (2013, 2014, 2015)
  • Table 8-20: Roche Revenues (2014 and 2015)
  • Table 8-21: Siemens Revenues (2014 and 2015)
  • Table 8-22: Sysmex Revenues (2013, 2014, 2015)
  • Table 8-23: Thermo Fisher Scientific Revenues (2013, 2014, 2015)
Back to Top